A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials
Abstrakt
Background: Definition of Pseudomonas aeruginosa (Pa) microbiological status is essential for patients' inclusion in clinical trials. The aim of this study was to agree on the definitions of Pa infection status for initial infection, eradication and chronic infection to be used in clinical trials and to propose additional future study areas.
Methods: An exhaustive literature search was performed. The clinimetric properties of different definitions of Pa microbiological status were evaluated.
Results: Historical studies have mostly used culture-based definitions, although some have also involved complementary anti-Pa antibodies. Clinimetric analysis showed great variability in the definitions used, leading to differences in reliability, validity, responsiveness to treatment and correlation with outcome measures.
Use of serology for initial Pa infection and successful Pa eradication introduced a greater level of complexity as antibody tests are not standardised. Moreover, the chronology of the immune response to Pa antigenic determinants was not completely clear.
Chronic Pa infection was characterized by high levels of antibodies and good concordance between culture results and serology. Conclusions: Microbiological monitoring, regular sampling from the airways and standardization of culture methods remain essential requisites for microbiological definitions.
Despite limitations, serology should be incorporated in the definitions of initial infection and eradication used in clinical trials to better classify patients at enrolment, mainly in non-expectorating children. This requires standardization of serological testing. (C) 2019 European Cystic Fibrosis Society.
Published by Elsevier B.V. All rights reserved.